Objective: A comprehensive assessment of the clinical，economic，patient and social value of using prophylaxis versus on-demand treatment in adult hemophilia A patients，with a view to informing research and application of prophylaxis in adult patients. Methods: Databases of CNKI，Wanfang，VIP，PubMed，and Embase were searched and relevant contents retrieved to summarize the evidence of clinical value，economic value，patient value and social value of adult hemophilia A patients who treated with prophylaxis Vs. treatment as needed. Results: In terms of clinical value，the use of prophylaxis in adults with hemophilia A is effective in reducing the number of bleeds，protecting joint function and reducing disability compared to on-demand treatment. In terms of economic value，the use of prophylaxis in adults with hemophilia A has a cost effectiveness advantage. In terms of patient value，the use of prophylaxis in adults with hemophilia A can improve self-care and mobility，resulting in greater social participation and a better quality of life for the patient. In terms of social value，the use of preventive therapy for adults with hemophilia A provides long-term productivity benefits by enabling patients to return to normal work，school and life. Conclusion: The use of prophylaxis in adults with hemophilia A has advantages in terms of clinical value，economic value，patient value and social value and should be actively pursued to benefit more adult patients.